Publication
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerGastrointestinal Stromal Tumorcivic_curation1.00
- drugImatinibcivic_curation1.00
- geneKITcivic_curation1.00
- variantKIT Exon 9 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 16624552
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KIT Exon 9 Mutation1 | ||||||||
| Imatinib | Gastrointestinal Stromal Tumor | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID1221In a phase III clinical trial comparing different doses of imatinib in GIST patients, KIT exon 9 mutations were associated with significantly improved progression free survival (P=0.0013) and a 61% re… (full text at CIViC) PMID 16624552 · Debiec-Rychter et al., 2006 · Open in CIViC | civic |
| KIT S501_A502INSAY1 | ||||||||
| Imatinib | Gastrointestinal Stromal Tumor | Predictive | B | Supports Resistance | — | submitted | EID2856Gastrointestinal stromal tumor (GIST) patients with exon 9 mutations in KIT were less likely to show a complete or partial response to imatinib (44.4% vs. 71.7%, P=0.007) and had a shorter time to tum… (full text at CIViC) PMID 16624552 · Debiec-Rychter et al., 2006 · Open in CIViC | civic |
| KIT Y503_F504insAY1 | ||||||||
| Imatinib | Gastrointestinal Stromal Tumor | Predictive | B | Supports Sensitivity Response | — | submitted | EID2394Patients with exon 9 mutations treated with a higher dose of imatinib (800mg vs. 400 mg daily) experienced improved progression-free survival compared to those treated with the standard dose (HR:0.392… (full text at CIViC) PMID 16624552 · Debiec-Rychter et al., 2006 · Open in CIViC | civic |